{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen X"],"funding":["Chen Xiao-Ping Foundation for The Development of Science and Technology of Hubei Province"],"pagination":["2543220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9236769"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2022"],"pubmed_abstract":["Sorafenib is the first-line therapeutic regimen targeting against advanced or metastatic stage of hepatocellular carcinoma (HCC). However, HCC patients at these stages will eventually fail sorafenib treatment due to the drug resistance. At present, molecular mechanisms underlying sorafenib resistance are not completely understood. Our past studies have shown that DJ-1 is upregulated in HCC, while DJ-1 knockdown inhibits HCC xenograft-induced tumor growth and regeneration, implying that DJ-1 may be a potential target in for HCC treatment. However, whether DJ-1 plays a regulatory role between tumor cells and vascular endothelial cells and whether DJ-1 contributes to sorafenib resistance in HCC cells are largely unclear. To address these questions, we have performed a series of experiments in"],"journal":["Oxidative medicine and cellular longevity"],"pubmed_title":["DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma."],"pmcid":["PMC9236769"],"funding_grant_id":["CXPJJH12000001-2020308","2016YXMS111","81602592","82174020","81602626"],"pubmed_authors":["Yang G","Zhang J","Guo X","Chen X","Sun W","Wang H","Liu S","Liu D"],"additional_accession":[]},"is_claimable":false,"name":"DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.","description":"Sorafenib is the first-line therapeutic regimen targeting against advanced or metastatic stage of hepatocellular carcinoma (HCC). However, HCC patients at these stages will eventually fail sorafenib treatment due to the drug resistance. At present, molecular mechanisms underlying sorafenib resistance are not completely understood. Our past studies have shown that DJ-1 is upregulated in HCC, while DJ-1 knockdown inhibits HCC xenograft-induced tumor growth and regeneration, implying that DJ-1 may be a potential target in for HCC treatment. However, whether DJ-1 plays a regulatory role between tumor cells and vascular endothelial cells and whether DJ-1 contributes to sorafenib resistance in HCC cells are largely unclear. To address these questions, we have performed a series of experiments in","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-22T05:54:45.861Z","creation":"2025-04-05T21:34:15.352Z"},"accession":"S-EPMC9236769","cross_references":{"pubmed":["35770048"],"doi":["10.1155/2022/2543220"]}}